Avascular Necrosis (Osteonecrosis) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Avascular necrosis (AVN) of the femoral head is caused by the interruption of blood supply to the bone of the proximal femur. The loss of blood supply can result from both traumatic and non-traumatic causes and leads to cell death (osteonecrosis). Significant necrosis leads to the total collapse of the overlying articular cartilage of the femoral head secondary to the underlying necrotic subchondral bone failure. This occurs before revascularization and regeneration of the necrotic bone can occur due to loss of the underlying structural rigidity of the affected bone as osteoclasts resorb it. The end result of this process is early osteoarthritis (OA) of the hip. The patient will often require a total hip replacement as the osteoarthritis progresses. AVN occurs in 15% to 50% of cases of femoral neck and head fractures and 10% to 25% of hip dislocations. Internal fixation is generally preferred in young patients to save the natural femoral head after a fracture. In contrast, in older patients and elderly patients, primary arthroplasty may be performed to restore mobility.

Total diagnosed avascular necrosis (AVN) cases range from 25,500 to 31,750 cases yearly in the USA.

 

The competitive landscape of Avascular Necrosis (Osteonecrosis) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Avascular Necrosis (Osteonecrosis) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Avascular Necrosis (Osteonecrosis) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Avascular Necrosis (Osteonecrosis) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          OSSGROW®    Regrow Biosciences      Phase 2

2          Ixmyelocel-T     Vericel Corporation        Phase 3

3          Core decompression/PREOB® implantation        Bone Therapeutics S.A       Phase 2

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033